Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Novavax, Inc. (NASDAQ: NVAX).

Full DD Report for NVAX

You must become a subscriber to view this report.


Recent News from (NASDAQ: NVAX)

Novavax: A Break In The Action
Buy The Decline Novavax ( NVAX ) is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company recently reported quarter 3 earnings earlier this month missing on revenue by $1.89 ...
Source: SeekingAlpha
Date: December, 03 2018 03:58
Novavax, Inc. (NVAX) CEO Stanley Erck on Q3 2018 Results - Earnings Call Transcript
Novavax, Inc. (NVAX) Q3 2018 Results Earnings Conference Call November 07, 2018, 04:30 PM ET Executives Erika Trahan - IR Stanley Erck - President and CEO John Trizzino - Senior VP, Chief Business Officer & CFO Gregory Glenn - President, Research and Development Amy Fix -...
Source: SeekingAlpha
Date: November, 07 2018 20:11
Novavax EPS in-line, misses on revenue
Novavax (NASDAQ: NVAX ): Q3 GAAP EPS of -$0.12 in-line. Revenue of $7.74M (-7.3% Y/Y) misses by $1.89M . Shares -2% . Press Release More news on: Novavax, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 07 2018 16:11
Novavax Reports Third Quarter 2018 Financial Results
Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter and nine months ended September 30, 2018. “We remain o...
Source: GlobeNewswire
Date: November, 07 2018 16:05
Notable earnings after Wednesday's close
AAOI , ADT , ALB , ALRM , AMBC , ANGI , ANSS , ARNA , ATO , AVID , AVLR , AYX , BREW , CABO , CARG , CASA , CISN , CSGS , CSOD , CTRP , CVNA , CYBR , DVA , ECPG , EDIT , ENS , ENV , ET , EVC , EVRG , FARM , FG , FLO , FLS , FOSL , GDOT , GKOS , HK , HO...
Source: SeekingAlpha
Date: November, 06 2018 17:35
Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2018
GAITHERSBURG, Md., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, November 7, 2018. Conference call details are as follows: C...
Source: GlobeNewswire
Date: November, 01 2018 16:15
Novavax Appoints Rachel King to Board of Directors
GAITHERSBURG, Md., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) today announced the appointment of Rachel King, Co-Founder and Chief Executive Officer of GlycoMimetics, Inc., to its Board of Directors. In addition to extensive experience as an executive in the biotechnolo...
Source: GlobeNewswire
Date: November, 01 2018 16:05
Research Report Identifies FS Investment, Rush Enterprises, GlycoMimetics, Federal Signal, ATN International, and Novavax with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FS Investment Corporation (NYSE:FSIC), Rush Enterprises, Inc. (NASDAQ:RUS...
Source: GlobeNewswire
Date: August, 31 2018 07:45
Novavax to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Novavax will participate in the B. Riley FBR Annual Healthcare Conference and the Citi 13 th Annual Biotech Conference in September. Conference details are as follows: About Novavax...
Source: GlobeNewswire
Date: August, 28 2018 16:05
Novavax: Burning Candle At Both Ends
As Novavax ( NVAX ) continues to make progress towards multiple vaccine approvals in the next couple of years, the stock isn't gaining any traction. The company finally mentioned finding a potential partner as the cash burn remains relentless. The biotech stock only gets interesting under th...
Source: SeekingAlpha
Date: August, 24 2018 11:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-142.272.402.492.269,285,578
2018-12-132.522.3252.582.3113,975,984
2018-12-122.302.4652.492.2515,793,131
2018-12-112.222.2252.322.1659,563,163
2018-12-102.062.122.202.038,563,162

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-141,606,6423,470,24246.2977Short
2018-12-132,041,5654,987,43840.9341Short
2018-12-121,945,3625,436,66335.7823Short
2018-12-111,220,9723,427,71935.6205Short
2018-12-101,358,7842,741,75549.5589Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NVAX.


About Novavax, Inc. (NASDAQ: NVAX)

Logo for Novavax, Inc. (NASDAQ: NVAX)

Not available

 

Contact Information

 

 

Current Management

  • Richard F. Maradie / CEO
  • Denis M. O Donnell / President, COO
  • Brenda L. Fugagli / CFO, COO
  • David A. White / Secretary

Current Share Structure

  • Market Cap: $591,236,384 - 05/18/2018
  • Issue and Outstanding: 343,742,084 - 03/09/2018

 


Recent Filings from (NASDAQ: NVAX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 08 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: August, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 24 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 15 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: June, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018

 

 


Daily Technical Chart for (NASDAQ: NVAX)

Daily Technical Chart for (NASDAQ: NVAX)


Stay tuned for daily updates and more on (NASDAQ: NVAX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NVAX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NVAX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NVAX and does not buy, sell, or trade any shares of NVAX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/